Question What is the rate of laboratory test result abnormalities in healthy adults and children taking terbinafine or
Results: This study included laboratory data from 4985 patients (mean [SD] age, 42
No baseline testing needed in the
Haematological dyscrasias and hepatic injury are possible adverse
Griseofulvin is only approved as a systemic (oral) agent and is indicated for the treatment of dermatophytoses of the skin, hair, and nails, which is severe or refractory to topical therapy
All abnormal laboratory results were mild and resolved with treatment discontinuation or completion
Reference ID: 3395060 ; Pyrexia 7 6 Cough 6 5 Vomiting 5 5 Disturbances in porphyrin metabolism have been reported in griseofulvin-treated laboratory animals
Although most side effects are mild and self-limited, such as headache and gastrointestinal symptoms, taste disturbances
Griseofulvin and terbinafine are considered effective first-line therapies for tinea capitis (TC)
Periodic monitoring of organ system function, including renal Griseofulvin is a fungistatic agent used to treat superficial fungal skin infections such as tinea capitis and pedis
induced, incr
Griseofulvin has been reported to have a colchicine-like effect on mitosis and was cocarcinogenic with methylcholanthrene in
Griseofulvin may cause serious side effects
Dispense griseofulvin oral suspension, USP in a tight, light-resistant container as defined in the USP
Methodology of Evaluating the Laboratory Monitoring of Terbinafine Therapy-Reply JAMA Dermatol
[9 19] How does the pharmacokinetics of griseofulvin differ in a child
Uses How to use Side effects Precautions Drug interactions Overdose Notes Missed dose Storage Important note
9%] female) receiving 4309 courses of terbinafine, 634 courses of griseofulvin microsize, and 159 courses of griseofulvin ultramicrosize